COMPANY PROFILE // THE 014 REPORT
Nektar Therapeutics
NKTR (Nasdaq) · Formerly: INHALE THERAPEUTIC SYSTEMS INC; INHALE THERAPEUTIC SYSTEMS
Assembled from 4 government sources in 2.6 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2025-04-04 (last 24 months).
- AmberLEI 5299005I24806IOIYE03 registration status is LAPSED (last update 2021-07-14): the legal-entity record has not been renewed.
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
✓ SEC filings✓ LEI✓ State registrationpossible match✓ Lobbying registrationpossible match✗ SAM registration✗ IRS return✗ Website
No SAM registration, no IRS return, no website on record.
NEKTAR THERAPEUTICS is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in San Francisco, CA; listed as NKTR (Nasdaq).[source] It reported revenue of $55.2 million for the fiscal year ended 2025-12-31.[source] It has filed 87 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-19.[source] 5 lobbying disclosure filings name a client with this company's exact name (possible match).[source] Its largest institutional holders on 13F filings are FMR LLC, Two Seas Capital LP, BlackRock, Inc. (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 3.01 filed; LEI 5299005I24806IOIYE03 registration status is LAPSED (last update 2021-07-14).[source]
- red0
- amber2
- info1
- FMR LLC$353.8M
- Two Seas Capital LP$215.9M
- BlackRock, Inc.$205.4M
- BVF INC/IL$166.9M
- VANGUARD CAPITAL MANAGEMENT LLC$104.5M
- TWO SIGMA INVESTMENTS, LP$83.9M
- Vestal Point Capital, LP$69.8M
- STATE STREET CORP$63.5M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough. (Wikipedia, CC BY-SA 4.0)
Officers and directors (Forms 3, 4, 5)
- ROBIN HOWARD W · President & CEO (Director,Officer) · latest Form 4 2026-02-20 · filing · LinkedIn search
- Wilson Mark Andrew · Chief Legal Officer (Officer) · latest Form 4 2025-11-25 · filing · LinkedIn search
- Zalevsky Jonathan · Chief R&D Officer (Officer) · latest Form 4 2026-02-20 · filing · LinkedIn search
- Ajer Jeffrey Robert · Director · latest Form 4 2025-10-01 · filing · LinkedIn search
- Brainard Diana · Director · latest Form 4 2025-10-01 · filing · LinkedIn search
- CHESS ROBERT · Director · latest Form 4 2025-10-01 · filing · LinkedIn search
- GREER R SCOTT · Director · latest Form 4 2025-10-01 · filing · LinkedIn search
- WHITFIELD ROY A · Director · latest Form 4 2025-10-01 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Goodwin Procter LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-10-20
Links
- Official website (Wikidata or the SEC record)
- Wikipedia
- Wikidata
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 24 CLEAR, 2 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0000906709 | source |
| LEI | 5299005I24806IOIYE03 | source |
| EIN | 94-3134940 | source |
| NY DOS ID | 5895353 | record |
| California SOS entity | 1216487-03-191-0455865 | record |
| California SOS entity | 0455865-01-001-0455865 | record |
| LDA clientpossible match | 203945 | record |
| LDA clientpossible match | 130873 | record |
| LDA clientpossible match | 165001 | record |
| Business address (SEC) | 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158 | source |
Does not exist in the records we hold: UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2019-10-10 · in -2,600 days · LEI next renewal (5299005I24806IOIYE03)
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Adverum Biotechnologies, Inc. · Rubinstein Linda M
- Twist Bioscience Corp · CHESS ROBERT
- Viridian Therapeutics, Inc.\DE · Ajer Jeffrey Robert
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-17 filing 144 · SEC EDGAR
- 2026-11-17 filing 144 · SEC EDGAR
- 2026-11-13 filing 8-K items 7.01 · SEC EDGAR
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-20 filing S-8 · SEC EDGAR
- 2026-10-01 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-09-25 filing 8-K items 8.01 · SEC EDGAR
- 2026-09-08 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-18 filing 144 · SEC EDGAR
- 2026-08-18 filing 144 · SEC EDGAR
- 2026-08-14 filing S-8 · SEC EDGAR
- 2026-08-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-13 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-06-30 filing 144 · SEC EDGAR
- 2026-06-17 filing 144 · SEC EDGAR
- 2026-06-16 filing 144 · SEC EDGAR
- 2026-06-15 filing 144 · SEC EDGAR
- 2026-06-05 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-19 filing 144 · SEC EDGAR
- 2026-05-19 filing 144 · SEC EDGAR
- 2026-05-08 filing 424B5 · SEC EDGAR
- 2026-05-08 officer change 8-K items 1.01,5.02,9.01 · SEC EDGAR
- 2026-05-08 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-24 filing ARS · SEC EDGAR
- 2026-04-24 filing DEFA14A · SEC EDGAR
- 2026-04-24 filing Proxy statement · SEC EDGAR
- 2026-04-23 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-04-23 filing 424B5 · SEC EDGAR
170 earlier entries
- 2026-04-20 filing 424B5
- 2026-04-20 filing 8-K items 7.01
- 2026-04-20 filing 8-K items 7.01,8.01,9.01
- 2026-03-13 filing 144
- 2026-03-13 filing Annual report (10-K)
- 2026-03-12 filing 8-K items 2.02,9.01
- 2026-02-18 filing 144
- 2026-02-18 filing 144
- 2026-02-13 filing 8-K items 1.01,8.01,9.01
- 2026-02-13 filing 424B5
- 2026-02-10 filing 424B5
- 2026-02-10 filing 8-K items 7.01
- 2026-02-10 filing 8-K items 7.01,8.01,9.01
- 2026-01-27 filing 8-K items 7.01,9.01
- 2026-01-20 filing 144
- 2025-12-16 filing 8-K items 7.01,8.01,9.01
- 2025-11-25 filing 144
- 2025-11-25 filing 144
- 2025-11-25 filing 144
- 2025-11-21 officer change 8-K items 5.02,9.01
- 2025-11-12 filing S-8
- 2025-11-12 filing 424B5
- 2025-11-12 filing S-3ASR
- 2025-11-10 filing 8-K items 7.01,8.01,9.01
- 2025-11-07 filing Quarterly report (10-Q)
- 2025-11-06 filing 8-K items 2.02,9.01
- 2025-10-01 insider First Form 3/4/5 on record for Ajer Jeffrey Robert (Director)
- 2025-10-01 insider First Form 3/4/5 on record for Brainard Diana (Director)
- 2025-10-01 insider First Form 3/4/5 on record for CHESS ROBERT (Director)
- 2025-10-01 insider First Form 3/4/5 on record for GREER R SCOTT (Director)
- 2025-10-01 insider First Form 3/4/5 on record for WHITFIELD ROY A (Director)
- 2025-09-18 filing 8-K items 7.01,8.01,9.01
- 2025-09-09 filing 144
- 2025-09-05 filing 144
- 2025-09-04 filing 144
- 2025-09-04 filing 144
- 2025-09-02 filing 144
- 2025-09-02 filing 144
- 2025-08-19 filing 144
- 2025-08-19 filing 144
- 2025-08-19 filing 144
- 2025-08-08 filing S-8
- 2025-08-08 filing Quarterly report (10-Q)
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-07-01 filing 8-K items 1.01,8.01,9.01
- 2025-07-01 filing 424B5
- 2025-06-30 filing 424B5
- 2025-06-27 filing 8-K items 8.01
- 2025-06-24 filing 8-K items 7.01,8.01,9.01
- 2025-06-06 filing 8-K items 5.03,9.01
- 2025-06-04 filing 8-K items 8.01
- 2025-05-28 filing 8-K items 5.07
- 2025-05-21 insider First Form 3/4/5 on record for ROBIN HOWARD W (President & CEO)
- 2025-05-21 insider First Form 3/4/5 on record for Wilson Mark Andrew (Chief Legal Officer)
- 2025-05-21 insider First Form 3/4/5 on record for Zalevsky Jonathan (Chief R&D Officer)
- 2025-05-19 filing 144
- 2025-05-19 filing 144
- 2025-05-19 filing 144
- 2025-05-09 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-04-25 filing ARS
- 2025-04-25 filing Proxy statement
- 2025-04-15 filing PRE 14A
- 2025-04-04 filing 8-K items 3.01
- 2025-04-01 filing EFFECT
- 2025-03-28 filing 8-K items 1.01,9.01
- 2025-03-28 filing CORRESP
- 2025-03-28 filing S-3
- 2025-03-20 filing UPLOAD
- 2025-03-14 filing DRSLTR
- 2025-03-14 filing DRS
- 2025-03-14 filing S-8
- 2025-03-14 filing Annual report (10-K)
- 2025-03-12 filing 8-K items 2.02,9.01
- 2025-02-24 filing 8-K items 8.01,9.01
- 2025-02-19 filing 144
- 2025-02-19 filing 144
- 2025-02-19 filing 144
- 2025-02-04 filing 8-K items 8.01,9.01
- 2024-12-26 filing 144
- 2024-12-23 filing 144
- 2024-12-19 filing 144
- 2024-12-18 filing 144
- 2024-12-17 filing 144
- 2024-12-02 filing 8-K items 2.01,9.01
- 2024-11-19 filing 144
- 2024-11-19 filing 144
- 2024-11-19 filing 144
- 2024-11-08 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-11-04 filing 8-K items 1.01,7.01,9.01
- 2024-08-19 filing 144
- 2024-08-19 filing 144
- 2024-08-19 filing 144
- 2024-08-09 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-06-14 filing 144
- 2024-06-06 filing 8-K items 5.07
- 2024-06-05 filing EFFECT
- 2024-06-05 filing 424B3
- 2024-06-03 filing CORRESP
- 2024-05-31 filing UPLOAD
- 2024-05-28 filing S-3
- 2024-05-17 filing 144
- 2024-05-17 filing 144
- 2024-05-17 filing 144
- 2024-05-10 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-04-26 filing ARS
- 2024-04-26 filing DEFA14A
- 2024-04-26 filing Proxy statement
- 2024-04-17 filing 8-K items 8.01
- 2024-03-19 filing D
- 2024-03-05 filing Annual report (10-K)
- 2024-03-04 filing 8-K items 1.01,2.02,9.01
- 2024-03-04 filing 8-K items 1.01,3.02,9.01
- 2024-02-20 filing 144
- 2024-02-20 filing 144
- 2024-02-20 filing 144
- 2024-02-16 filing 8-K items 1.02,8.01
- 2024-01-10 filing 8-K items 2.02,7.01
- 2023-12-15 filing 144
- 2023-11-27 filing 8-K items 3.01
- 2023-11-17 filing 144
- 2023-11-17 filing 144
- 2023-11-17 filing 144
- 2023-11-08 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 2.02,9.01
- 2023-09-18 filing 144
- 2023-09-08 filing 8-K items 1.02
- 2023-08-14 filing S-8
- 2023-08-09 filing Quarterly report (10-Q)
- 2023-08-08 filing 8-K items 2.02,9.01
- 2023-08-07 filing 8-K items 7.01,8.01,9.01
- 2023-06-23 officer change 8-K items 5.02
- 2023-06-14 filing 144
- 2023-06-09 filing 8-K items 5.07
- 2023-06-02 filing 8-K items 3.01
- 2023-05-10 filing Quarterly report (10-Q)
- 2023-05-09 filing 8-K items 2.02,9.01
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing Proxy statement
- 2023-04-27 filing 8-K items 1.02,7.01,9.01
- 2023-04-17 officer change 8-K items 2.02,2.05,5.02,7.01,9.01
- 2023-04-11 officer change 8-K items 5.02
- 2023-03-13 filing 8-K items 8.01,9.01
- 2023-02-28 filing 8-K items 2.02,9.01
- 2023-02-28 filing Annual report (10-K)
- 2023-02-23 filing 8-K items 7.01,8.01,9.01
- 2023-01-09 filing 8-K items 2.02,7.01
- 2022-12-22 filing 8-K items 8.01
- 2022-12-16 filing 8-K items 5.03,9.01
- 2022-11-04 filing Quarterly report (10-Q)
- 2022-11-03 filing 8-K items 2.02,9.01
- 2022-10-11 filing 8-K items 7.01,9.01
- 2022-10-07 filing 8-K items 7.01,9.01
- 2022-08-05 filing S-8
- 2022-08-05 filing Quarterly report (10-Q)
- 2022-08-04 filing 8-K items 2.02,9.01
- 2022-07-01 officer change 8-K items 5.02
- 2022-06-10 filing 8-K items 5.07
- 2022-05-23 filing 8-K items 8.01
- 2022-05-06 filing Quarterly report (10-Q)
- 2022-05-05 filing 8-K items 2.02,9.01
- 2022-05-02 filing 8-K items 2.05,2.06
- 2022-04-29 filing DEFA14A
- 2022-04-29 filing Proxy statement
- 2022-04-25 officer change 8-K items 2.02,5.02,7.01,9.01
- 2022-04-14 filing 8-K items 8.01,9.01
- 2022-03-14 filing 8-K items 8.01,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 30 days) 8-K filed: Item 7.01 Regulation FD disclosure
- 2026-11-13 (within 30 days) 10-Q filed
- 2026-11-12 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-20 (older) S-8 filed (REGISTRATION STATEMENT)
- 2026-10-01 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-25 (older) 8-K filed: Item 8.01 other event
- 2026-09-08 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-14 (older) S-8 filed (REGISTRATION STATEMENT)
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:NKTR The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
15 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 906709 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | NKTR / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 5299005I24806IOIYE03 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 5299005I24806IOIYE03) | GLEIF |
| LEI | 3358001DORBTZPX4C839 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 3358001DORBTZPX4C839) | GLEIF |
| EIN | 943134940 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000906709 | SEC EDGAR / IRS |
| CUSIP | 640268306 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0000906709 | SEC EDGAR |
possible match: matched by name only, not merged (9)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| LDA client id | 203945 (NEKTAR THERAPEUTICS (lobbying via BGR GOVERNMENT AFFAIRS)) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | Lobbying Disclosure Act (LDA) |
| LDA client id | 111215 (NEKTAR THERAPEUTICS (lobbying via CAPITOL ASSOCIATES, INC.)) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | Lobbying Disclosure Act (LDA) |
| LDA client id | 165001 (NEKTAR THERAPEUTICS (lobbying via MERCURY PUBLIC AFFAIRS, LLC)) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | Lobbying Disclosure Act (LDA) |
| LDA client id | 158831 (NEKTAR THERAPEUTICS (lobbying via QGA PUBLIC AFFAIRS (FORMERLY QUINN GILLESPIE & ASSOCIATES))) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | Lobbying Disclosure Act (LDA) |
| LDA client id | 130873 (NEKTAR THERAPEUTICS (lobbying via an individual registrant)) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | Lobbying Disclosure Act (LDA) |
| EPA FRS id | 110020424842 (NEKTAR THERAPEUTICS) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | EPA ECHO facilities |
| EPA FRS id | 110003030764 (NEKTAR THERAPEUTICS) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | EPA ECHO facilities |
| EPA FRS id | 110038090268 (NEKTAR THERAPEUTICS) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | EPA ECHO facilities |
| EPA FRS id | 110041657007 (NEKTAR THERAPEUTICS) | name-exact:legal-name: same registered legal name as 'NEKTAR THERAPEUTICS' | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $55,232,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-22 09:23 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$164,076,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 09:23 UTC | Report an error |
| Total assets (at 2025-12-31) | $280,406,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 09:23 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $89,832,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 09:23 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $15,116,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 09:23 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:23 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:23 UTC | Report an error |
| State of incorporation | DE | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:23 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:23 UTC | Report an error |
| Business address | 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:23 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-22 09:23 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$208,511,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 09:23 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $171,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 09:23 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $85,751,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 09:23 UTC | Report an error |
| Form D total offering amount (D filed 2024-03-19) | $30,000,000 | 2024-03-19 | D | as filed | 2026-11-22 09:23 UTC | Report an error |
| Form D total amount sold (D filed 2024-03-19) | $30,000,000 | 2024-03-19 | D | as filed | 2026-11-22 09:23 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2024-03-19 | D | as filed | 2026-11-22 09:23 UTC | Report an error |
| Form D revenue range | $25,000,001 - $100,000,000 | 2024-03-19 | D | as filed | 2026-11-22 09:23 UTC | Report an error |
| Form D date of first sale | 2024-03-04 | 2024-03-19 | D | as filed | 2026-11-22 09:23 UTC | Report an error |
| Plan (pension, plan no. 001) | NEKTAR THERAPEUTICS 401(K) PLAN: 676 participants, assets $148,236,479 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-22 09:23 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001193125-26-458868
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $9,386,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001193125-26-458868 | 2026-11-22 09:23 UTC | Report an error |
| Net income (loss) | -$55,651,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001193125-26-458868 | 2026-11-22 09:23 UTC | Report an error |
| Cash and cash equivalents | $34,686,000 | at 2026-09-30 | 10-Q | 2026-11-13 | 0001193125-26-458868 | 2026-11-22 09:23 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing 8-K filed: Item 7.01 Regulation FD disclosure
- 2026-11-13 Filing 10-Q filed
- 2026-11-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-20 Filing S-8 filed (REGISTRATION STATEMENT)
- 2026-10-01 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-09-25 Filing 8-K filed: Item 8.01 other event
- 2026-09-08 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-14 Filing S-8 filed (REGISTRATION STATEMENT)
- 2026-08-14 Filing 10-Q filed
- 2026-08-13 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-28 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-06-05 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-08 Filing 424B5 filed
- 2026-05-08 Filing 8-K filed: Item 1.01 material agreement; Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-05-08 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-24 Filing ARS filed
- 2026-04-24 Filing DEFA14A filed
- 2026-04-24 Filing DEF 14A filed
- 2026-04-23 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-04-23 Filing 424B5 filed
- 2026-04-20 Filing 424B5 filed
- 2026-04-20 Filing 8-K filed: Item 7.01 Regulation FD disclosure
- 2026-04-20 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-03-13 Filing 10-K filed
2 earlier entries
- 2026-03-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 1994-02-15 Record plan effective date: NEKTAR THERAPEUTICS 401(K) PLAN
8-K item text, as filed (excerpts)
- 2026-11-13 8-K Item 7.01, Regulation FD
In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics (the “Company”) reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consistent with its prior guidance, the Company expects that this cash balance will extend its cash runway into the third quarter of 2028 past the initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis in the summer of 2028. The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the… the 8-K · retrieved 2026-11-22 09:23 UTC - 2026-11-12 8-K Item 2.02, Results of Operations and Financial
Condition. On November 12, 2026, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2026. A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by… the 8-K · retrieved 2026-11-22 09:23 UTC - 2026-10-01 8-K Item 7.01, Regulation FD Disclosure
On October 1, 2026, Nektar Therapeutics (the “Company”) issued a press release reporting new data from its Phase 2b REZOLVE-AA (alopecia areata) clinical trial. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. On October 1, 2026, the Company made available a presentation that includes certain additional information regarding its Phase 2b REZOLVE-AA (alopecia areata) clinical trial. A copy of this presentation is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K. This presentation is also available on the investor relations section of the Company’s website at https://ir.nektar.com/. Information contained on the… the 8-K · retrieved 2026-11-22 09:23 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · NAME ONLY6. Lobbying (LDA)
5 lobbying records carry this company's exact name, hiring 5 lobbying firms. These are possible matches until the accuracy score, so they are not counted in the headline.
possible match: matched by name only, not merged (5)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchNEKTAR THERAPEUTICS (lobbying via BGR GOVERNMENT AFFAIRS) · exact legal name · sx:lda:203945 Compare
- possible matchNEKTAR THERAPEUTICS (lobbying via CAPITOL ASSOCIATES, INC.) · exact legal name · sx:lda:111215 Compare
- possible matchNEKTAR THERAPEUTICS (lobbying via MERCURY PUBLIC AFFAIRS, LLC) · exact legal name · sx:lda:165001 Compare
- possible matchNEKTAR THERAPEUTICS (lobbying via QGA PUBLIC AFFAIRS (FORMERLY QUINN GILLESPIE & ASSOCIATES)) · exact legal name · sx:lda:158831 Compare
- possible matchNEKTAR THERAPEUTICS (lobbying via an individual registrant) · exact legal name · sx:lda:130873 Compare
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (4)
possible match: matched by name only, not merged (4)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchNEKTAR THERAPEUTICS · exact legal name · sx:epa:110020424842 Compare
- possible matchNEKTAR THERAPEUTICS · exact legal name · sx:epa:110003030764 Compare
- possible matchNEKTAR THERAPEUTICS · exact legal name · sx:epa:110038090268 Compare
- possible matchNEKTAR THERAPEUTICS · exact legal name · sx:epa:110041657007 Compare
EPA RCRA hazardous waste (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchNEKTAR THERAPEUTICS · exact legal name · sx:rcra:CAR000208934 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $353,791,520 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 2 | Two Seas Capital LP | $215,868,856 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 3 | BlackRock, Inc. | $205,370,620 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 4 | BVF INC/IL | $166,920,946 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $104,495,029 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 6 | TWO SIGMA INVESTMENTS, LP | $83,911,899 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 7 | Vestal Point Capital, LP | $69,810,000 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 8 | STATE STREET CORP | $63,504,691 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $61,536,312 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
| 10 | Prosight Management, LP | $56,546,100 | 2026-06-30 | SEC 13F filing | 2026-11-22 09:23 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
2 legal entities in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- NEKTAR THERAPEUTICS · LEI 5299005I24806IOIYE03 · root
- NEKTAR THERAPEUTICS (INDIA) PRIVATE LIMITED · LEI 3358001DORBTZPX4C839
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
5 state and city records carry this company's exact name, from 4 sources. Possible matches only.
California business registrations (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchNektar Therapeutics · exact legal name · sx:cabiz:sf:1216487-03-191-0455865 Compare
- possible matchNektar Therapeutics · exact legal name · sx:cabiz:sf:0455865-01-001-0455865 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchNektar Therapeutics · exact legal name · sx:ctgov:hf14e7fb31669da7a Compare
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchNektar Therapeutics · exact legal name · sx:elic:ctcred:2226762 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchNEKTAR THERAPEUTICS · exact legal name · sx:nydos:5895353 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/906709.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0000906709. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.